CytRx Corporation (CYTR) Tops Q3 EPS by 3c
More News related to CYTR
- CytRx to Initiate Phase 2 Clinical Trial with INNO-206 in Patients with Advanced Gastric Cancer
- CytRx Corporation (CYTR) Tops Q3 EPS by 3c
- CytRx Reports 2009 Third Quarter Financial Results
- CytRx Announces Publication of Paper Stating that Chaperone Amplification Represents a 'Significant Strategy' in Anti-aging Pharmaceutical Design
- CytRx Fortifies Executive Suite with Addition of Chief Medical Officer
More News related to Earnings
- Highlights From SJM's Q2 Conference Call: Acquisition of Folger's Really Paying Off; Comfortable Raising FY Outlook
- Highlights From INTU's Q1 Conference Call: Issues Mixed Guidance for Q2, In-line for FY10
- Highlights From The GAP's (GPS) Q3 Conference Call: Total Comp-Store Sales Were Flat Vs. Down 12% Last Year
- Highlights From DELL's Q3 Conference Call: Revenues Adversely Affected By Timing of Windows 7 Launch
- D. R. Horton (DHI) Home Orders Rise, But Losses Continue
CytRx Corporation (NASDAQ: CYTR) reports Q3 EPS of $0.04, 3 cents better than estimates. Revenues were $7.0 million vs. $4.95 million consensus.
[SM]
Related Categories
EarningsStocks Mentioned
+0.23Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
